10X Genomics Inc (TXG)

Currency in USD
25.35
+0.55(+2.22%)
Closed·
25.23-0.12(-0.46%)
·

NASDAQ:TXG Financials

Key Ratios

P/E Ratio-72.66
Price/Book3.73
Debt / Equity10.59%
Return on Equity-5.78%
Dividend Yield0.00%
EBITDA-64.09M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
2025
31/12
* In Millions of USD (except for per share items)

Analyst Ratings

6 Buy
10 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 21.69
(-14.43% Downside)

Earnings

Latest Release
Feb 12, 2026
EPS / Forecast
-0.13 / -0.22
Revenue / Forecast
166M / 157.73M
EPS Revisions
Last 90 days

FAQ

What were 10X Genomics's earnings for the latest quarter?

The 10X Genomics EPS (TTM) is -0.35. 10X Genomics reported sales of The 10X Genomics EPS (TTM) is -0.35. 10X Genomics reported sales of 166.03, net income of -16.25, and EPS of -0.13 for the latest quarter., net income of -16.25, and EPS of -0.13 for the latest quarter.

What was 10X Genomics's net income for the latest quarter?

10X Genomics's net income for the latest quarter was -16.25.

How did 10X Genomics's performance compare year-over-year in the latest quarter?

The company's revenue moved from 149.00 million USD in the previous quarter to 166.03 million USD in the latest quarter, and net income moved from -27.47 million USD to -16.25 million USD compared to the previous quarter.

What is 10X Genomics's net profit margin on a TTM basis?

10X Genomics's trailing twelve months (TTM) net profit margin is -6.77%%.

How does 10X Genomics's debt to equity ratio compare to industry standards?

10X Genomics's total debt-to-equity ratio is 10.59%.

What is 10X Genomics's return on investment on a TTM basis?

10X Genomics's trailing twelve months (TTM) return on investment (ROI) is -5.78%.

What is 10X Genomics's gross margin on a TTM basis?

10X Genomics's trailing twelve months (TTM) gross margin is 69.13%%.

What was 10X Genomics's revenue per share for the latest quarter?

10X Genomics's revenue per share for the latest quarter was 33.56.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.